{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:25:43Z","timestamp":1792074343972,"version":"4.4.0"},"reference-count":126,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The proteasome is crucial for the degradation of intracellular proteins and plays an important role in mediating a number of cell survival and progression events by controlling the levels of key regulatory proteins such as cyclins and caspases in both normal and tumor cells. However, compared to normal cells, cancer cells are more dependent on the ubiquitin proteasome pathway (UPP) due to the accumulation of proteins in response to uncontrolled gene transcription, allowing proteasome to become a potent therapeutic target for human cancers such as multiple myeloma (MM). Up to date, three proteasome inhibitors namely bortezomib (2003), carfilzomib (2012) and ixazomib (2015) have been approved by the US Food and Drug Administration (FDA) for the treatment of patients with relapsed and\/or refractory MM. This review mainly focuses on the biochemical properties, mechanism of action, toxicity profile and pivotal clinical trials related to carfilzomib, a second-generation proteasome inhibitor that binds irreversibly with proteasome to overcome the\u00a0major toxicities and resistance associated with bortezomib.<\/jats:p>","DOI":"10.3389\/fonc.2021.740796","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T12:55:48Z","timestamp":1636548948000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":89,"title":["Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma"],"prefix":"10.3389","volume":"11","author":[{"given":"Shansa Pranami E.","family":"Jayaweera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacheela Prasadi","family":"Wanigasinghe Kanakanamge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharshika","family":"Rajalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri N.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple Myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.6004\/jnccn.2018.0002","article-title":"NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018","volume":"16","author":"Kumar","year":"2018","journal-title":"J Natl Compr Cancer Netw"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0049","article-title":"NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020","volume":"17","author":"Kumar","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"B5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev.pharmtox.051208.165340","article-title":"Targeting Proteins for Destruction by the Ubiquitin System: Implications for Human Pathobiology","volume":"49","author":"Schwartz","year":"2009","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nrd2056","article-title":"Drug Discovery in the Ubiquitin - Proteasome System","volume":"5","author":"Nalepa","year":"2006","journal-title":"Nat Rev Drug Discovery"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome Inhibitors in Cancer Therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent Activity of Carfilzomib, a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway, Against Preclinical Models of Multiple Myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130281","article-title":"Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Multiple Myeloma","volume":"72","author":"McBride","year":"2015","journal-title":"Am J Heal Syst Pharm"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/17474086.2021.1858790","article-title":"A Comprehensive Overview of Daratumumab and Carfilzomib and the Recently Approved Daratumumab, Carfilzomib and Dexamethasone Regimen in Relapsed\/Refractory Multiple Myeloma","volume":"14","author":"Richard","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195008","article-title":"A Monoclonal Gammopathy Precedes Multiple Myeloma in Most Patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal Gammopathy of Undetermined Significance (MGUS) Consistently Precedes Multiple Myeloma: A Prospective Study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa070389","article-title":"Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","article-title":"Current Treatment Landscape for Relapsed and\/or Refractory Multiple Myeloma","volume":"12","author":"Dimopoulos","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0004","article-title":"Multiple Myeloma, Version 1.2013","volume":"11","author":"Anderson","year":"2013","journal-title":"J Natl Compr Cancer Netw"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.303","article-title":"Relapsed Multiple Myeloma","volume":"2010","author":"Lonial","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.12688\/f1000research.6835.1","article-title":"Intracellular Dynamics of the Ubiquitin-Proteasome-System[version 2; Peer Review: 3 Approved]","volume":"4","author":"Chowdhury","year":"2015","journal-title":"F1000Research"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.03.009","article-title":"Structural Complexity in Ubiquitin Recognition","volume":"124","author":"Harper","year":"2006","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/bcr460","article-title":"The Role of the Ubiquitination-Proteasome Pathway in Breast Cancer: Applying Drugs That Affect the Ubiquitin-Proteasome Pathway to the Therapy of Breast Cancer","volume":"5","author":"Orlowski","year":"2002","journal-title":"Breast Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clml.2018.08.016","article-title":"Role of Proteasome Inhibitors in Relapsed and\/or Refractory Multiple Myeloma","volume":"19","author":"Leleu","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.blre.2013.10.002","article-title":"Targeting the Ubiquitin Proteasome System in Haematological Malignancies","volume":"27","author":"Crawford","year":"2013","journal-title":"Blood Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12079-011-0121-7","article-title":"Proteasome\u00a0Inhibitors in Cancer Therapy","volume":"5","author":"Crawford","year":"2011","journal-title":"J Cell\u00a0Commun Signal"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2018.01.004","article-title":"Proteasome Inhibitors: Structure and Function","volume":"44","author":"Nunes","year":"2017","journal-title":"Semin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107579","article-title":"The Proteasome as a Druggable Target With Multiple Therapeutic Potentialities: Cutting and non-Cutting Edges","volume":"213","author":"Tundo","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201490736","article-title":"Reprogramming of Human Cancer Cells to Pluripotency for Models of Cancer Progression","volume":"34","author":"Kim","year":"2015","journal-title":"EMBO J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg227","article-title":"For Whom the Bell Tolls: Protein Quality Control of the Endoplasmic Reticulum and the Ubiquitin-Proteasome Connection","volume":"22","author":"Kostova","year":"2003","journal-title":"EMBO J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.12.26","article-title":"Role of Carfilzomib in the Treatment of Multiple Myeloma","volume":"5","author":"Khan","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1334037100","article-title":"Proteasome Inhibitors Disrupt the Unfolded Protein Response in Myeloma Cells","volume":"100","author":"Lee","year":"2003","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome Inhibitors Induce a Terminal Unfolded Protein Response in Multiple Myeloma Cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902895780","article-title":"Dysregulation of Unfolded Protein Response Partially Underlies Proapoptotic Activity of Bortezomib in Multiple Myeloma Cells","volume":"50","author":"Dong","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212470388","article-title":"Carfilzomib: A New Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma","volume":"19","author":"Steele","year":"2013","journal-title":"J Oncol Pharm Pract"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.1209038","article-title":"The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation","volume":"334","author":"Walter","year":"2011","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2321","article-title":"Ubiquitin-Proteasome System Stress Sensitizes Ovarian Cancer to Proteasome Inhibitor-Induced Apoptosis","volume":"66","author":"Bazzaro","year":"2006","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.12.013","article-title":"Repurposing Old Drugs as New Inhibitors of the Ubiquitin-Proteasome Pathway for Cancer Treatment","volume":"68","author":"Yang","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally High Expression of Proteasomes in Human Leukemic Cells","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016360","article-title":"Circulating Proteasome Levels are an Independent Prognostic Factor for Survival in Multiple Myeloma","volume":"109","author":"Jakob","year":"2007","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI11991","article-title":"Control of Oncogenesis and Cancer Therapy Resistance by the Transcription Factor NF-\u03bab","volume":"107","author":"Baldwin","year":"2001","journal-title":"J Clin Invest"},{"key":"B41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrc1588","article-title":"Nuclear Factor-\u03bab Inhibitors as Sensitizers to Anticancer Drugs","volume":"5","author":"Nakanishi","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb07287.x","article-title":"Phosphorylation of Human I\u03bab-\u03b1 on Serines 32 and 36 Controls I\u03bab-\u03b1 Proteolysis and NF-\u03bab Activation in Response to Diverse Stimuli","volume":"14","author":"Traenckner","year":"1995","journal-title":"EMBO J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(94)90482-0","article-title":"The Ubiquitin-Proteasome Pathway is Required for Processing the NF-\u03bab1 Precursor Protein and the Activation of NF-\u03bab","volume":"78","author":"Palombella","year":"1994","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The Development of Proteasome Inhibitors as Anticancer Drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1177\/1947601910382902","article-title":"Ubiquitin-Dependent Proteolysis in G1\/S Phase Control and its Relationship With Tumor Susceptibility","volume":"1","author":"Diehl","year":"2010","journal-title":"Genes Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81519-6","article-title":"Cdk Phosphorylation Triggers Sequential Intramolecular Interactions That Progressively Block Rb Functions as Cells Move Through G1","volume":"98","author":"Harbour","year":"1999","journal-title":"Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0913","article-title":"Cyclin D1 Degradation is Sufficient to Induce G1 Cell Cycle Arrest Despite Constitutive Expression of Cyclin E2 in Ovarian Cancer Cells","volume":"69","author":"Masamha","year":"2009","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/1747-1028-7-26","article-title":"Therapeutic Targeting of Cancer Cell Cycle Using Proteasome Inhibitors","volume":"7","author":"Rastogi","year":"2012","journal-title":"Cell Div"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0676","article-title":"Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells","volume":"65","author":"Qin","year":"2005","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4322","article-title":"Noxa Up-Regulation and Mcl-1 Cleavage are Associated to Apoptosis Induction by Bortezomib in Multiple Myeloma","volume":"67","author":"Gomez-Bougie","year":"2007","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210744","article-title":"BCL-2 Family Regulation by the 20S Proteasome Inhibitor Bortezomib","volume":"27","author":"Fennell","year":"2008","journal-title":"Oncogene"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.5.3130","article-title":"Proteasomes Modulate Balance Among Proapoptotic and Antiapoptotic Bcl-2 Family Members and Compromise Functioning of the Electron Transport Chain in Leukemic Cells","volume":"166","author":"Marshansky","year":"2001","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.197","article-title":"Assay of Matrix Metalloproteases Types 8 and 9 by ELISA in Human Breast Cancer","volume":"71","author":"Duffy","year":"1995","journal-title":"Br J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular Mechanisms Mediating Antimyeloma Activity of Proteasome Inhibitor PS-341","volume":"101","author":"Hideshima","year":"2003","journal-title":"Blood"},{"key":"B55","article-title":"The Proteasome Inhibitor PS-341 Inhibits Growth, Induces Apoptosis, and Overcomes Drug Resistance in Human Multiple Myeloma Cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I","article-title":"Regulation of the Cdk Inhibitor P27 and its Deregulation in Cancer","volume":"183","author":"Slingerland","year":"2000","journal-title":"J Cell Physiol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2657","article-title":"P21 in Cancer: Intricate Networks and Multiple Activities","volume":"9","author":"Abbas","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.05.003","article-title":"PCNA, the Maestro of the Replication Fork","volume":"129","author":"Moldovan","year":"2007","journal-title":"Cell"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501034102","article-title":"Recruitment of DNA Methyltransferase I to DNA Repair Sites","volume":"102","author":"Mortusewicz","year":"2005","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B60","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/3-540-31390-7_11","article-title":"Cytosine Methylation and DNA Repair","volume-title":"DNA Methylation: Basic Mechanisms. Current Topics in Microbiology and Immunology","author":"Walsh","year":"2006"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202445099","article-title":"Molecular Sequelae of Proteasome Inhibition in Human Multiple Myeloma Cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.46","article-title":"Noxa: At the Tip of the Balance Between Life and Death","volume":"27","author":"Ploner","year":"2008","journal-title":"Oncogene"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403109","article-title":"The Proteasome Inhibitor Bortezomib Promotes Mitochondrial Injury and Apoptosis Induced by the Small Molecule Bcl-2 Inhibitor HA14-1 in Multiple Myeloma Cells","volume":"17","author":"Pei","year":"2003","journal-title":"Leukemia"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4914(02)02315-8","article-title":"Proteasome Inhibition: A Novel Approach to Cancer Therapy","volume":"8","author":"Adams","year":"2002","journal-title":"Trends Mol Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1361","article-title":"The Proteasome: A Suitable Antineoplastic Target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2221","article-title":"Nuclear Factor-\u03bab in Development, Prevention, and Therapy of Cancer","volume":"13","author":"Van Waes","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"B68","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0959-8049(02)00503-8","article-title":"Changing Concepts in Multiple Myeloma: From Conventional Chemotherapy to High-Dose Treatment","volume":"39","author":"Sonneveld","year":"2003","journal-title":"Eur J Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2018.03.002","article-title":"Next-Generation Proteasome Inhibitors for Cancer Therapy","volume":"198","author":"Park","year":"2018","journal-title":"Transl Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/426218","article-title":"Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the Clinic","volume":"2010","author":"Allan","year":"2010","journal-title":"J Oncol"},{"key":"B71","article-title":"Cyclodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors","volume-title":"United States US 2015o11 1838a1 Pat Appl Publ","author":"Lewis","year":"2015"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.09.022","article-title":"Effects of Organic Acids on Drug Release From Ternary Polypeptide Nanoparticles Entrapping Carfilzomib","author":"Jackson","year":"2021","journal-title":"J\u00a0Pharm Sci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2018.12.003","article-title":"Preparation and Optimization of Poly (Lactic Acid) Nanoparticles Loaded With Fisetin to Improve Anti-Cancer Therapy","volume":"125","author":"Feng","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223677","article-title":"Carfilzomib can Induce Tumor Cell Death Through Selective Inhibition of the Chymotrypsin-Like Activity of the Proteasome","volume":"114","author":"Parlati","year":"2009","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S150653","article-title":"Carfilzomib for Relapsed and Refractory Multiple Myeloma","volume":"11","author":"Groen","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B76","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-409547-2.12395-9","article-title":"Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer","volume-title":"Comprehensive Medicinal Chemistry III","author":"Pasqua","year":"2017"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1021\/ja993588m","article-title":"Crystal Structure of Epoxomicin:20S Proteasome Reveals a Molecular Basis for Selectivity of \u03b1\u2019,\u03b2\u2019-Epoxyketone Proteasome Inhibitors","volume":"122","author":"Groll","year":"2000","journal-title":"J Am Chem Soc"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf8993","article-title":"The Inhibition Mechanism of Human 20 S Proteasomes Enables Next-Generation Inhibitor Design","volume":"353","author":"Schrader","year":"2016","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201600488","article-title":"High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design","volume":"17","author":"Carmony","year":"2016","journal-title":"ChemBioChem"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12072","article-title":"Carfilzomib: A Novel Agent for Multiple Myeloma","volume":"65","author":"Redic","year":"2013","journal-title":"J Pharm Pharmacol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M509043200","article-title":"Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies With the Protein Substrate","volume":"281","author":"Kisselev","year":"2006","journal-title":"J Biol Chem"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.039164","article-title":"Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats","volume":"39","author":"Yang","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0424-9","article-title":"Tissue Distribution and Depletion Kinetics of Bortezomib and Bortezomib-Related Radioactivity in Male Rats After Single and Repeated Intravenous Injection of 14C-Bortezomib","volume":"60","author":"Hemeryck","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-459883","article-title":"Carfilzomib","volume":"121","author":"Kortuem","year":"2013","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.226993","article-title":"Polymer Micelle Formulations of Proteasome Inhibitor Carfilzomib for Improved Metabolic Stability and Anticancer Efficacy in Human Multiple Myeloma and Lung Cancer Cell Lines","volume":"355","author":"Ao","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"B86","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/leu.2017.212","article-title":"Carfilzomib Resistance Due to ABCB1\/MDR1 Overexpression is Overcome by Nelfinavir and Lopinavir in Multiple Myeloma","volume":"32","author":"Besse","year":"2018","journal-title":"Leukemia"},{"key":"B87","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1038\/s41598-019-40635-1","article-title":"H727 Cells are Inherently Resistant to the Proteasome Inhibitor Carfilzomib, Yet Require Proteasome Activity for Cell Survival and Growth","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or Bortezomib in Relapsed or Refractory Multiple Myeloma (ENDEAVOR): An Interim Overall Survival Analysis of an Open-Label, Randomised, Phase 3 Trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934","article-title":"A Phase 2 Study of Single-Agent Carfilzomib (PX-171-003-A1) in Patients With Relapsed and Refractory Multiple Myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-414359","article-title":"An Open-Label, Single-Arm, Phase 2 (PX-171-004) Study of Single-Agent Carfilzomib in Bortezomib-Naive Patients With Relapsed and\/or Refractory Multiple Myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.176","article-title":"A Randomized Phase III Study of Carfilzomib vs Low-Dose Corticosteroids With Optional Cyclophosphamide in Relapsed and Refractory Multiple Myeloma (FOCUS)","volume":"31","author":"H\u00e1jek","year":"2017","journal-title":"Leukemia"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1411321","article-title":"Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma (ENDEAVOR): A Randomised, Phase 3, Open-Label, Multicentre Study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Et al. Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients With Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Interim Analysis Results of a Randomised, Phase 3 Study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma (CANDOR): Results From a Randomised, Multicentre, Open-Label, Phase 3 Study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, Carfilzomib, and Dexamethasone in Relapsed Multiple Myeloma (IKEMA): A Multicentre, Open-Label, Randomised Phase 3 Trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients With Hematologic Malignancies","volume":"15","author":"O\u2019Connor","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3007","article-title":"A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma or Lymphoma","volume":"18","author":"Alsina","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.08.003","article-title":"An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma","volume":"12","author":"Jagannath","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.3522","article-title":"Phase I Study of 30-Minute Infusion of Carfilzomib as Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and\/or Refractory Multiple Myeloma","volume":"33","author":"Papadopoulos","year":"2015","journal-title":"J Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1182\/blood-2014-02-556308","article-title":"A Phase 2 Single-Center Study of Carfilzomib 56 Mg\/M2 With or Without Low-Dose Dexamethasone in Relapsed Multiple Myeloma","volume":"124","author":"Lendvai","year":"2014","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001965","article-title":"Efficacy and Safety of Carfilzomib-Based Regimens in Frail Patients With Relapsed and\/or Refractory Multiple Myeloma","volume":"4","author":"Facon","year":"2020","journal-title":"Blood Adv"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-683854","article-title":"CHAMPION-1: A Phase 1\/2 Study of Once-Weekly Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma","volume":"127","author":"Berenson","year":"2016","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020265","article-title":"Proteasome Inhibitors for the Treatment of Multiple Myeloma","volume":"12","author":"Ito","year":"2020","journal-title":"Cancers"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3352","article-title":"Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma","volume":"19","author":"Niesvizky","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-511170","article-title":"Phase 2 Dose-Expansion Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma","volume":"122","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hon.2820","article-title":"A Real-World Efficacy and Safety Analysis of Combined Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Relapsed\/Refractory Multiple Myeloma","volume":"39","author":"Rocchi","year":"2021","journal-title":"Hematol Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0431","article-title":"Isatuximab Plus Carfilzomib\/Dexamethasone Versus Carfilzomib\/Dexamethasone in Patients With Relapsed\/Refractory Multiple Myeloma: IKEMA Phase III Study Design","volume":"16","author":"Moreau","year":"2019","journal-title":"Futur Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated Safety Profile of Single-Agent Carfilzomib: Experience From 526 Patients Enrolled in 4 Phase II Clinical Studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1437269","article-title":"Cardiotoxicity Associated With Carfilzomib: Systematic Review and Meta-Analysis","volume":"59","author":"Shah","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B115","doi-asserted-by":"publisher","first-page":"e8767","DOI":"10.1371\/journal.pone.0087671","article-title":"Incidence and Risk of Cardiotoxicity Associated With Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-Analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"PloS One"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.card","article-title":"Heart Failure With Carfilzomib in Patients With Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials","volume":"27","author":"Rahman","year":"2021","journal-title":"J Card Fail"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003269","article-title":"Cardiac and Renal Complications of Carfilzomib in Patients With Multiple Myeloma","volume":"1","author":"Dimopoulos","year":"2017","journal-title":"Blood Adv"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858415","article-title":"Molecular Mechanisms of Carfilzomib-Induced Cardiotoxicity in Mice and the Emerging Cardioprotective Role of Metformin","volume":"133","author":"Efentakis","year":"2019","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04062-x","article-title":"Risk of Kidney Toxicity With Carfilzomib in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials","volume":"99","author":"Ball","year":"2020","journal-title":"Ann Hematol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04420-3\/Published","article-title":"Renal Failure Among Multiple Myeloma Patients Utilizing Carfilzomib and Associated Factors in the \u201cReal World","volume":"100","author":"Mian","year":"2021","journal-title":"Ann Hematol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1528229","article-title":"Ixazomib for the Treatment of Multiple Myeloma","volume":"19","author":"Richardson","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S49187","article-title":"An Evidence-Based Review of Ixazomib Citrate and its Potential in the Treatment of Newly Diagnosed Multiple Myeloma","volume":"7","author":"Offidani","year":"2014","journal-title":"Onco Targets Ther"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S93602","article-title":"Spotlight on Ixazomib: Potential in the Treatment of Multiple Myeloma","volume":"10","author":"Muz","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.60","article-title":"Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib","volume":"5","author":"Kumar","year":"2015","journal-title":"Blood Cancer J"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1864355","article-title":"Ixazomib, Lenalidomide, and Dexamethasone Is Effective and Well Tolerated in Multiply Relapsed (\u22652nd Relapse) Refractory Myeloma: A Multicenter Real World UK Experience","volume":"62","author":"Maouche","year":"2021","journal-title":"Leuk Lymphoma"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.740796\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T12:55:53Z","timestamp":1636548953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.740796\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":126,"alternative-id":["10.3389\/fonc.2021.740796"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.740796","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"article-number":"740796"}}